Literature DB >> 21366462

Expression and phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 in B-cell lymphomas and reactive lymphoid tissues.

Dhatri Kodali1, Ajay Rawal, Mary J Ninan, Manish R Patel, Hector Mesa, Dennis Knapp, Bertram Schnitzer, Robert A Kratzke, Pankaj Gupta.   

Abstract

CONTEXT: Cap-mediated messenger RNA translation controlled by the eukaryotic initiation factor 4F (eIF-4F) complex plays a key role in human cancer. eIF-4F activity is controlled by a repressor binding protein (4E-BP1), which promotes translation when phosphorylated.
OBJECTIVE: To examine the level of expression and phosphorylation of 4E-BP1 in various subtypes of B-cell lymphoma and reactive lymphoid tissues.
DESIGN: Archival formalin-fixed, paraffin-embedded B-cell lymphoma samples and reactive lymphoid tissues were immunostained and examined for expression of 4E-BP1 and phosphorylated 4E-BP1. Expression of components of the eIF-4F complex and unphosphorylated and phosphorylated 4E-BP1 was confirmed using Western immunoblotting on lysates of frozen lymphoma samples and reactive tissues.
RESULTS: Immunohistochemical analysis demonstrated weak to undetectable 4E-BP1 staining within benign, reactive germinal centers (N = 10). In contrast, 4E-BP1 was consistently expressed (moderate to strong staining) in 98% of various subtypes of mature B-cell lymphoma (N = 50). 4E-BP1 expression was also demonstrable in all 4 lymph nodes with in situ or partial involvement by follicular lymphoma and in all 12 cases of BCL2-negative lymphoma. The level of phosphorylation of 4E-BP1 in lymphomas, evaluated by immunohistochemistry, was heterogeneous.
CONCLUSIONS: The immunohistochemical expression pattern of 4E-BP1 exhibits regional and cellular specificity in reactive lymphoid tissues and may offer a diagnostic tool for distinguishing reactive follicles from neoplastic B-cell proliferations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21366462     DOI: 10.5858/2009-0759-OA.1

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Different effects of histone deacetylase inhibitors nicotinamide and trichostatin A (TSA) in C17.2 neural stem cells.

Authors:  Haifeng Wang; Hua Cheng; Kai Wang; Tieqiao Wen
Journal:  J Neural Transm (Vienna)       Date:  2012-03-13       Impact factor: 3.575

2.  Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.

Authors:  Christos Demosthenous; Jing Jing Han; Mary J Stenson; Matthew J Maurer; Linda E Wellik; Brian Link; Kristen Hege; Ahmet Dogan; Eduardo Sotomayor; Thomas Witzig; Mamta Gupta
Journal:  Oncotarget       Date:  2015-04-20

3.  Expression profile of translation initiation factor eIF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcome.

Authors:  Julia J Unterluggauer; Katharina Prochazka; Peter V Tomazic; Heinrich J Huber; Rita Seeboeck; Karoline Fechter; Elisabeth Steinbauer; Verena Gruber; Julia Feichtinger; Martin Pichler; Marc A Weniger; Ralf Küppers; Heinz Sill; Rudolf Schicho; Peter Neumeister; Christine Beham-Schmid; Alexander J A Deutsch; Johannes Haybaeck
Journal:  Blood Cancer J       Date:  2018-08-22       Impact factor: 11.037

4.  Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms.

Authors:  Joe Taylor; Alison M Yeomans; Graham Packham
Journal:  Explor Target Antitumor Ther       Date:  2020-02-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.